Tascom Co (XKRX:336040) Debt-to-Equity : 0.00 (As of . 20)

View and export this data going back to 2019. Start your Free Trial

What is Tascom Co Debt-to-Equity?

Tascom Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₩0.00 Mil. Tascom Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₩0.00 Mil. Tascom Co's Total Stockholders Equity for the quarter that ended in . 20 was ₩0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Tascom Co's Debt-to-Equity or its related term are showing as below:

XKRX:336040's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.29
* Ranked among companies with meaningful Debt-to-Equity only.

Tascom Co Debt-to-Equity Historical Data

The historical data trend for Tascom Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tascom Co Debt-to-Equity Chart

Tascom Co Annual Data

Trend

Debt-to-Equity

Tascom Co Semi-Annual Data

Debt-to-Equity

Competitive Comparison of Tascom Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Tascom Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tascom Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tascom Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Tascom Co's Debt-to-Equity falls into.

Tascom Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Tascom Co's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/	N/A
	=	N/A

Tascom Co's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/
	=	N/A

Tascom Co (XKRX:336040) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Tascom Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Tascom Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tascom Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tascom Co Ltd (XKRX:336040) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

43 BanPo-daero 28-gil, 5th Floor, i-SENS Building, SeoCho-gu, Seoul, KOR

Website

http://www.yidobio.com

Tascom Co Ltd, formerly YIDOBIO Inc is a diabetes specialty company in Korea. The company develop cell therapy for the treatment of diabetes. It also manufactures and distributes diabetic supplies. The company's products include Blood glucose measurement system-acuraview, BD Ultra Fine PRO Pen Needle, Syringes-BD Ultrafine Syringes, Ido Sharp Container, and Ido safety lancet.

Tascom Co Headlines

No Headlines